Mannose‐Modified Multi‐Walled Carbon Nanotubes as a Delivery Nanovector Optimizing the Antigen Presentation of Dendritic Cells by Dong, Zhipeng et al.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
Mannose-Modified Multi-Walled Carbon Nanotubes as a
Delivery Nanovector Optimizing the Antigen Presentation
of Dendritic Cells
Zhipeng Dong,[a] Qiyan Wang,[a] Ming Huo,[a] Nanxia Zhang,[a] Bingxia Li,[a] Hongmei Li,[a]
Yisong Xu,[a] Meng Chen,[b] Hao Hong,*[c] and Yue Wang*[a]
Dendritic cells (DCs) based cancer immunotherapy is largely
dependent on adequate antigen delivery and efficient induction
of DCs maturation to produce sufficient antigen presentation
and ultimately lead to substantial activation of tumor-specific
CD8+ T cells. Carbon nanotubes (CNTs) have attracted great
attention in biomedicine because of their unique physicochem-
ical properties. In order to effectively deliver tumor antigens to
DCs and trigger a strong anti-tumor immune response, herein, a
specific DCs target delivery system was assembled by using
multi-walled carbon nanotubes modified with mannose which
can specifically bind to the mannose receptor on DCs
membrane. Ovalbumin (OVA) as a model antigen, could be
adsorbed on the surface of mannose modified multi-walled
carbon nanotubes (Man-MWCNTs) with a large drug loading
content. This nanotube-antigen complex showed low cytotox-
icity to DCs and was efficiently engulfed by DCs to induce DCs
maturation and cytokine release in vitro, indicating that it could
be a potent antigen-adjuvant nanovector of efficient antigen
delivery for therapeutic purpose.
Introduction
Cancer immunotherapy represents the most novel exciting
therapeutic modality for treating cancer.[1] Aiming at promoting
specific and long-lasting immunity against cancer through
stimulating the patients’ inherent immune system to recognize
and eliminate tumor cells, cancer immunotherapy is now
considered as an ideal therapeutic strategy against various
types of cancer.[2–4] T cells, especially cytotoxic CD8+ T cells
which can directly kill target tumor cells and acquire a long-
lasting memory phenotype responding to cancer recurrence,
play a vital role in antitumor immune response.[5] Hence, how to
efficiently generate enough robust cytotoxic CD8+ T cells is the
main challenge of this strategy.
Known as the most professional and important antigen
presenting cells (APCs), dendritic cells (DCs) are critical in
initiating adaptive immune responses through activating naive
T cells.[6] After capturing tumor antigen, DCs will present them
in the form of a major histocompatibility complex (MHC)/
peptide complex on their surface and finally elicit effective
activation of both CD8+ and CD4+ T lymphocytes.[7] Therefore,
enough tumor antigen presentation by DCs is critical in
initiating antitumor immune response. Previous studies have
shown that most tumors can evade recognition by the immune
system via expressing low levels of antigenic epitopes, MHC,
and co-stimulatory molecules, making them become poorly
immunogenic to DCs.[8] In this regard, sufficient delivery of
tumor antigen to DCs, which can efficiently induce DCs
maturation and cross-presentation, is the key strategy of cancer
immunotherapy.
Upon contact with antigens like pathogens or tumor cells,
DCs can recognize and internalize them via several mechanisms.
The phagocytosis of pathogens mediated by pattern recogni-
tion receptors (PRRs) such as Toll-like receptors (TLRs), NOD-like
receptors (NLRs), C-type lectin receptors (CLRs) and others are
crucial for the induction of proper DC maturation.[9] Among
them, through carbohydrate recognition domains (CRDs) in
their extracellular carboxy-terminal domains, CLRs could bind
sugar moieties on the surface of certain pathogens in a
calcium-dependent manner, lead to pathogen internalization
via receptor mediated endocytosis and subsequent degrada-
tion, and finally present the pathogen as antigen to T cells in
the context of MHC I or MHC II, or both.[10] As a member of C-
type lectin receptors predominantly expressed by DCs, man-
nose receptor (MR) can recycle continuously between the
plasma membrane and endosomal compartments in a clathrin-
dependent manner, leading to more effective internalization
and surface presentation of antigens by immature DCs and
finally resulting in enhanced T cell activation.[11–12] Thus,
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targeting to MR could be a powerful strategy to induce
antigen-specific immune response.
In the past few decades, a variety of nanoparticles (NPs)
based drug delivery systems have been developed for their
superior properties of enhancing therapeutic outcomes such as
improving loading drug’s safety, prolonging circulation time
and promoting bioavailability.[13–15] Carbon nanotubes (CNTs), as
a type of nanomaterial with unique physical and chemical
properties, have attracted a lot of interest in biomedical
applications.[16] Their intrinsic properties make them convenient
to internalize into a wide variety of cell types. Simultaneously,
they have a large available surface area for chemical modifica-
tion. Furthermore, extremely high surface area to volume ratio
of CNTs can provide multiple attachment sites for various
bioactive molecules such as proteins,[17] nucleic acids[18] and free
drugs,[19] along with protecting them against enzymatic degra-
dation, thus resulting in a superior intracellular biostability.
Besides, their remarkable conductive properties making them
have boosting effect on conductive tissue such as neural
tissues.[20–22] All of these fantastic properties make CNTs
available as a kind of candidate vehicle to be used in vaccine
development. The preparation of carbon nanotube derivatives
is usually carried out by introducing a carboxyl group by
oxidation, followed by modification of other molecules. Another
classical approach is to directly bind surfactants, nucleic acids,
peptides, polymers or oligomers in a non-covalent manner.[23–24]
Recently, there have also been reports on the use of carbon
nanotubes for the delivery of antigens, but most of them just
modified simply to increase their water solubility, which makes
them less effective in antigen delivery.[25–27]
In this study, we developed multi-walled carbon nanotubes
(MWCNTs) modified with mannose (Man-MWCNTs) as a specific
target delivery system to DCs. Compared with passive target
delivery, decorating with targeting ligands which can actively
recognize specific receptors on the target cell is much more
efficient.[28] Chicken egg ovalbumin (OVA), a standard antigenic
protein,[29] was chosen and loaded onto Man-MWCNTs.
(Scheme 1) It was found that this system could be highly
engulfed by DCs and efficiently induce DCs maturation in vitro,
demonstrating its potential as an antigen-adjuvant nanovector
for further application in vaccine development.
Results and Discussion
Preparation and Characterization of Man-MWCNTs/OVA
Man-MWCNTs were prepared from the oxidation of MWCNTs
followed by modification with mannosylated ethylenediamine.
(Figure 1) Fourier-transform infrared spectroscopy (FT-IR) spec-
tra were recorded using a pressed disk of powder combined
with KBr. As shown in Figure 2, the stretching vibration peaks of
O   H at 3500 cm  1 and C=O at 1630 cm  1 showed the
existence of carboxyl. After modification with mannosylated
ethylenediamine, the peak at 3500 cm  1 decreased and the
stretching vibration peak of N  H and C  N appeared at
3200 cm  1 and 1365 cm  1, intimating the carboxyl was con-
verted to anamide after functionalization. These results were
also verified by thermogravimetric analysis (Figure 3) and are
consistent with similar literature.[30] MWCNTs showed almost no
significant weight loss in low temperature, while MWCNTs-
COOH showed one weight loss platform (from 30 °C to 140 °C,
5.395%) which is due to carboxyl groups. In the curve of Man-
MWCNTs, the weight loss is similar to MWCNTs-COOH but
slightly increased (from 30 °C to 180 °C, 6.572%), indicating that
some of the carboxyl groups have been amidated by mannosy-
lated ethylenediamine.
Elemental analysis determined the contents of C, H and N
elements in Man-MWCNTs were 75.62 wt%, 1.33 wt% and
1.86 wt%, respectively. XPS was further performed to analyze
Scheme 1. Schematic illustration of Man-MWCNTs as an antigen delivery
nanovector to DCs.
Figure 1. Synthesis of Man-MWCNTs.
Figure 2. Infrared spectra of MWCNTs-COOH and Man-MWCNTs.
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the chemical compositions of the uppermost surface of the
nanotubes. As shown in Figure 4a, the main peaks of C1s and
O1s photoelectrons can be observed in the scanning spectra of
MWCNTs-COOH and Man-MWCNTs. Deconvolution of high-
resolution XPS spectra over the C1s region for all samples was
conducted, as shown in Figure 4b and 4c. The C1s spectra have
each been resolved into at five individual component peaks
that represent carbon in graphite at 284.5 eV, carbon in
aliphatic structures at 285.4 eV, carbon in phenolic, alcohol,
ether at 286.8 eV, carbon in carboxyl, lactone, or ester groups at
288.7 eV, and satellite peaks due to π-π* transitions in aromatic
rings at 291.2 eV (π-π* transition). The deconvolution of XPS
O1s peaks gives additional information on the nature of the
surface oxygen-containing groups. Figure 4d and 4e show the
O1s spectrum of all samples, which can be deconvoluted into
the following bands: carbonyl oxygen atoms at 531.1 eV,
carbonyl oxygen atoms in carboxyls and amides at 532.4 eV and
oxygen atoms in hydroxyls or ethers at 533.3 eV.[31] In addition,
the slight peak of N1s photoelectrons can be observed in the
spectrum of Man-MWCNTs, while in the corresponding area of
MWCNTs-COOH nothing appears except noise signals (Fig-
ure 4a). The spectra of N1s in Man-MWCNTs could be
deconvoluted into two bands, amide at 400.2 eV and amine at
407.2 eV (Figure 4f), which is also the evidence of the successful
amidation of carboxyl groups by mannosylated
ethylenediamine.[32]
OVA was then chosen as a model antigen to couple to NTs
for testifying its efficiency. The successful loading of OVA on
nanotubes was observed by TEM (Figure 5). The exposed
nanotubular morphology of Man-MWCNTs was clearly shown in
Figure 5b, which has no obvious difference from MWCNTs
(Figure 5a). While after interacting with OVA, Man-MWCNTs
surface was finally coated with protein layers (Figure 5c). The
calculation showed that the drug loading efficiency is approx-
imately 22.8%, indicating that much higher amount of protein
could be loaded on the nanotubes’ surface compared with
others nanovectors.[33–35] The drug release profile showed that
the Man-MWCNTs could prolong the release time of OVA and
reached a cumulative release of approximately 35% at 72 h,
which would help to produce long-lasting anti-tumor immune
response (Figure S1).
The change of zeta potential also demonstrated the
successful modification and protein covering of MWCNTs.
Surface charge is typically quantified by the zeta potential, a
parameter that provides information on the net charge of
particles in a liquid environment. Its value is closely related to
suspension stability and particle surface coating.[36] As shown in
Figure 6, the zeta potential of original MWCNTs was about
  21 mV. After oxidation, the potential has changed to   42 mV,
which supported the above FT-IR result that there was a large
amount of carboxyl groups on the surface of the nanotubes.
Figure 3. Thermogravimetric profiles of MWCNTs, MWCNTs-COOH and Man-
MWCNTs.
Figure 4. Results of XPS analysis of the MWCNTs-COOH and Man-MWCNTs:
(a) XPS survey scan spectra of MWCNTs-COOH and Man-MWCNTs. The inset
is magnification of the N1s region in MWCNTs-COOH and Man-MWCNTs
spectrum. (b,c) High resolution fitted XPS C1s spectra of MWCNTs-COOH and
Man-MWCNTs. (d,e) High resolution fitted XPS O1s spectra of MWCNTs-
COOH and Man-MWCNTs. (f) High resolution fitted XPS N1s spectra of Man-
MWCNTs.
Figure 5. TEM images of (a) MWCNTs, (b) Man-MWCNTs and (c) Man-
MWCNTs/OVA
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The potential increased to   34 mV after modification of
mannose, indicating that some of the carboxyl have been
esterified with mannose. Furthermore, when the surface of
Man-MWCNTs was covered by OVA, the zeta potential of Man-
MWCNTs/OVA increased to   20 mV.
In Vitro Cytotoxicity Research
To study the potential cytotoxicity of nanotubes, BMDCs were
treated with various concentrations of Man-MWCNTs and Man-
MWCNTs/OVA for 12 hours. The corresponding concentrations
of OVA were also tested under the same conditions in order to
eliminate its interference. As shown in Figure 7a, OVA showed
no significant toxicity to BMDCs at all concentrations. Figure 7b
showed that in both tests, with 100 μg/mL of nanotubes, more
than 60% of cells remained viable after incubation, which
indicated that those nanotubes did not exert significant
cytotoxicity on BMDCs. It is desirable that the loading of OVA
slightly reduced the toxicity of carbon nanotubes.
Mannose-Modification Promoted Antigen Uptake in BMDCs
In order to investigate whether the modification of mannose
could enhance the uptake of MWCNTs, OVA was prelabeled by
FITC and used to form the MWCNTs/OVA complex, which was
then incubated with BMDCs. The flow cytometric analysis in
Figure 8 showed that the OVA uptake by BMDCs was signifi-
cantly enhanced when OVA was loaded on MWCNTs, which is
due to the ability of carbon nanotubes to internalize into cells
through passive mechanisms like endocytic or needlelike
penetration.[37] Moreover, uptake of OVA by mannose-modified
MWCNTs increased more than unmodified ones, suggesting
that modification of the target molecular-mannose could
extremely enhance the binding of NTs and DCs through ligand/
receptor interactions of mannose. The similar results were also
revealed in confocal fluorescent microscope images (Figure 9).
Higher intracellular green fluorescent intensity could be
observed in cells treated with MWCNTs-COOH/OVA than OVA
owing to the convenient internalization of MWCNTs, while the
strongest FITC fluorescence intensity also appeared in the
mannose-modified group. Furthermore, we could observe that
some of the FITC labeled proteins and nanotubes were in the
same position, which confirms that the proteins were indeed
coated on the surface of the nanotubes and could be released
after being endocytosed by BMDCs. Moreover, the green
fluorescence (OVA) and red fluorescence (endosomes or
lysosomes) do not completely coincide in cells treated with
Man-MWCNTs/OVA, indicating that the nanotubes may help
antigens escape from endosomes to cytoplasm, which is
essential for exogenous antigens to be loaded onto MHC Class I
molecules and finally induce CD8+ cell response.[38] All these
Figure 6. Zeta potentials of MWCNTs, MWCNTs-COOH, Man-MWCNTs and
Man-MWCNTs/OVA.
Figure 7. Cytotoxicity of (a) OVA, (b) Man-MWCNTs and Man-MWCNTs/OVA
internalized by BMDCs.
Figure 8. Flow cytometric analysis of FITC-labeled OVA in BMDCs incubated
with OVA, MWCNTs-COOH/OVA, and Man-MWCNTs/OVA for 4 h.
Figure 9. Confocal images of BMDCs incubated with FITC-labeled OVA,
MWCNTs-COOH/FITC-OVA, and Man-MWCNTs/FITC-OVA for 4 h. Later endo-
somes and lysosomes (red) were stained with lysoTacker-Red, while OVA
(green) were prelabeled with FITC. Nuclei (blue) were stained with DAPI.
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results demonstrated that compared with OVA and MWCNTs-
COOH/OVA, Man-MWCNTs/OVA could significantly increase
antigen uptake of BMDCs via active surface binding.
Man-MWCNTs/OVA Induced BMDCs Maturation
In view of the fact that Man-MWCNTs has good biocompatibility
and can effectively increase antigen uptake of BMDCs by target
delivery, we investigated its antigen presenting effect on
BMDCs in vitro. Immature DCs are powerful antigen-capturing
cells, while mature DCs mainly act as antigen-presenting cells.
After capturing pathogens or tumor cells, immature DCs will
become mature DCs in the progress of migration from the
periphery to draining lymph nodes and then present antigens
through MHC complex to naive T lymphocytes, and finally
initiate subsequent immune responses.[39] Thus, the level of DCs
maturation is a quite important index to evaluate the immune
response in DC-based immunotherapy.
DC maturation is associated with a wide range of cellular
changes, one of them is the upregulation of co-stimulatory
molecules (CD80, CD86) on DCs membrane.[40] Figure 10
showed that in our experiments, the percent of matured DCs
(CD11c+CD80+CD86+) significantly increased from 26.9% to
62.2%, while the DC maturation level of those treated by the
same dose of free OVA was only increased to 36.3%, suggesting
that Man-MWCNTs/OVA-stimulated BMDCs may induce much
stronger immune responses owing to the increasing uptake of
antigen caused by Man-MWCNTs.
During the process of antigen-presentation, antigens will
promote the activation and maturation of DCs, which not only
results the expression of co-stimulatory molecules, but also
leads to the secretion of cytokines.[41] It has been demonstrated
that interleukin 1β (IL-1β) plays a significant role in the
activation of natural killer cells for efficient priming of Th1 cells
and CTLs,[42] while interleukin 6 (IL-6) is convinced to stimulate
the proliferation of activated B cells to secrete antibodies and
promote T cell proliferation and CTL activation.[43] Tumor
necrosis factor alpha (TNF-α) plays an important role in
promoting the expression of T cell MHC class I antigen and
enhancing the proliferation of IL-2-dependent thymocyte and T
cell.[44–45] To investigate the level of these cytokines, the culture
supernatants of BMDCs were harvested after various treatment
and then analyzed by an enzyme-linked immunosorbent assay
(ELISA). As shown in Figure 11, the levels of IL-1β, IL-6 and TNF-
α secreted by BMDCs significantly increased after Man-
MWCNTs/OVA treatment. Our results taken together suggest
that Man-MWCNTs could effectively help OVA promote DC
maturation and cytokine secretion to trigger a stronger immune
effect by increasing DC uptake.
Conclusions
Novel DCs-targeted nanovector were fabricated by modifying
the surface of MWCNTs with mannose. A high drug loading
content of OVA was observed owing to the large surface area of
MWCNTs. The ability of this carbon nanotube as an antigen
carrier to induce and enhance DCs activation by specific
interactions with the mannose receptor was investigated. Cell
affinity experiment showed the modification of mannose
greatly enhanced OVA target delivery to DCs, followed with the
efficiently enhanced DCs maturation and cytokines secretion.
All of these showed that Man-MWCNTs could be considered as
a promising vehicle for antigen delivery, which offers new
opportunities for tumor-specific antigen loading to induce an
effective immune response in vivo.
Experimental Section
Materials
All reagents and solvents were commercially available and used
without additional treatment. Multi-walled Carbon Nanotubes
(length, 0.5–2 μm; diameter, <8 nm) was purchased from XFNANO
(Nanjing, China). D-mannose, N-(3-dimethylaminopropyl)-N-ethyl-
carbodiimide (EDC), 2-(N-morpholino) ethanesulfonic acid (MES)
and fluorescein isothiocyanate (FITC) were purchased from Aladdin.
N-hydroxysuccinimide (NHS) was purchased from Macklin.
Phosphate Buffered Saline (PBS) (1×), RPMI-1640 medium, heat
inactivated fetal bovine serum (FBS), trypsin EDTA 0.05%, penicillin/
Figure 10. Quantification of CD80+ and CD86+ expression, which are
markers for DC maturation on the surface of BMDCs (CD11c+) after in vitro
incubation with OVA, Man-MWCNTs, or Man-MWCNTs/OVA for 12 h by flow
cytometry.
Figure 11. Secretion of IL-1β, IL-6 and TNF-α in suspensions of BMDCs after
in vitro incubation with OVA, Man-MWCNTs, or Man-MWCNTs/OVA for 24 h
by ELISA.
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streptomycin (PEST) 10,000 Unit/mL/10,000 mg/mL were purchased
from Gibco. Recombinant mouse granulocyte-macrophage colony-
stimulating factor (GM-CSF) and interleukin 4 (IL-4) were purchased
from R&D. Fluorochrome-labeled anti-mouse monoclonal antibod-
ies (CD11c, CD80 and CD86) were purchased from eBioscience.
Anti-mouse ELISA kits interleukin-1β (IL-1β), interleukin-6 (IL-6) and
tumor necrosis factor alpha (TNF-α) were purchased from R&D. All
other chemicals used in this study were of analytical reagent grade
and were used as received.
Characterization
Infrared spectra (4000–400 cm  1) were recorded on Bruker Fourier-
transform infrared (FT-IR) in KBr pellets. Thermogravimetric analysis
(TGA, NETZSCH, TG209 C) was conducted in air from 30 °C to 850 °C
at a rate of 10 °Cmin  1. The X-ray photoelectron spectroscopy (XPS,
UlVAC-PHI, PHI 5000 VersaProbe) measurement was performed to
analyze the surface properties quantitatively. Transmission electron
microscopy (TEM) was performed on a JEOL-2100 with accelerating
voltage of 200 kV. TEM samples were prepared by drop-casting
dispersion onto copper grids covered by carbon film. Confocal
images were acquired using a Zeiss confocal laser scanning unit
mounted on an LSM 710 fixed-stage upright microscope (CLSM).
Flow cytometry experiments were performed with a BD FACS Aria II
apparatus.
Preparation of Mannose-Modified Multi-Walled Carbon
Nanotubes (Man-MWCNTs)
MWCNTs-COOH was prepared by the oxidation of MWCNTs using
nitric acid. Briefly, 100 mg MWCNTs was dissolved in 50 mL nitric
acid, then stirred at 120 °C for 10 h. The products were collected by
centrifugation (8000 rpm, 5 min) and washed with deionized water
for three times. In order to synthesis Man-MWCNTs, mannose was
first prepared as a mannosylated ethylenediamine according to an
established method.[46] After that, MWCNTs-COOH (0.5 mg/mL) was
completely dispersed in MES buffer (10 mM, pH 6.0) using an
ultrasound bath. EDC (5 mg/mL) and NHS (5 mg/mL) were added
and then the mixture was stirred at room temperature for 24 h. The
products were collected by centrifugation (10,000 rpm, 5 min) and
washed with deionized water for three times. The obtained
nanotubes were dispersed in MES buffer and mannosylated ethyl-
enediamine (5 mg/mL) was added, then the mixture was stirred at
room temperature for 36 h. The products were collected by
centrifugation (11,000 rpm, 5 min) and washed with deionized
water for three times.
OVA Loading of Man-MWCNTs (Man-MWCNTs/OVA)
Man-MWCNTs/OVA was obtained after loading ovalbumin protein
on the surface of NTs via physical adsorption. Typically, Man-
MWCNTs and OVA was dissolved in deionized water with the ratio
of 1 : 1(w/w). The mixture was stirred at room temperature. After
10 h, the mixture was centrifuged at 14,000 rpm for 5 min. The
concentration of protein adsorbed on the nanotube was deter-
mined by subtracting the concentration of protein remaining in the
supernatant (estimated by BCA protein assay) from the total
concentration of added protein. Drug loading content (DLC) was
calculated according to the following formula: DLC(%)= (weight of
loaded OVA/weight of CNTs)×100%.
The in vitro release behavior of OVA was evaluated using the
following method: a 5 mg sample of Man-MWCNTs/OVA aqueous
solution was infused into a dialysis bag and dialyzed against
phosphate-buffered saline (PBS) with a pH value of 7.4 at 37 °C on
an orbital shaker. At each interval time point over a period of 72 h,
the concentration of OVA in the dialysate was measured by
ultraviolet spectroscopy. The total volume of dialysis was main-
tained at 50 mL through the test.
Generation of Bone Marrow Derived Dendritic Cells (BMDCs)
In Vitro
All animal experiments were performed in compliance with the
local ethics committee. Dendritic cells were generated from the
bone marrow (BM) of 6- to 8-week-old C57BL/6 mice (18–20 g,
Nanjing Mu Tu Medical Science and Technology Co.) according to
an established method.[47] Briefly, the femur and tibia were obtained
under aseptic conditions and the marrow cells were flushed using
RPMI 1640. After treated with red blood cell lysis solution, cells
were cultured in six-well plates in complete medium with
granulocyte-macrophage colony-stimulating factor (GM-CSF) and
interleukin 4 (IL-4) at 2×106 cells/4 mL/well. On day 3, the culture
medium was replaced by 4 mL fresh medium containing GM-CSF.
On day 5, half of the culture medium was harvested and replaced
by 2 mL fresh medium containing GM-CSF. On day 7, most of the
cells were differentiated into BMDCs and ready for use.
Cell Viability Assay
CCK-8 assay was employed in this experiment to quantitatively
evaluate the cell viability. BMDCs were treated with Man-MWCNTs
or Man-MWCNTs/OVA with various concentrations for 12 h in 96-
well culture plates under the same conditions, respectively. After
incubation, 10 μL CCK-8 was added and cultured for another 2 h.
The optical density of the solution was measured by enzyme linked
immunosorbent assay (ELISA) at a wavelength of 450 nm. The
absorbance value of untreated cells was set at 100%. Each
experiment was repeated three times in sextuplicate (n=6).
Confocal Imaging
To detect the intracellular localization of antigen in BMDCs, OVA
was pre-labeled with fluorescein isothiocyanate (FITC). Briefly, FITC
and OVA was dissolved in 20 mmol/L carbonate buffer (0.5 M,
pH 9.5) with the ratio of 1 :1(w/w). The solution was incubated with
continuous stirring at room temperature for 24 h in the dark. The
reaction mixture was dialyzed against distilled water (MWCO 3500)
to obtain FITC-OVA.
BMDCs were cultured with FITC-OVA, MWCNTs-COOH/FITC-OVA or
Man-MWCNTs/FITC-OVA at 37 °C for 4 h. At the end of the experi-
ment, the cells were labeled with 50 nM Lyso-Tracker Red for
60 min to visualize late endosomes and lysosomes. The nuclei were
stained with DAPI for 15 min and fluorescent images were recorded
by a confocal laser scanning microscopy.
Flow Cytometry Assay
To detect intracellular OVA signals, FITC-OVA, MWCNTs-COOH/FITC-
OVA or Man-MWCNTs/FITC-OVA was incubated with BMDCs for 4 h.
After washing the BMDCs with FACS buffer (phosphate buffer saline
(PBS) containing 1% FBS), the cellular fluorescence was measured
by FCM analysis.
To measure the effects of Man-MWCNTs/OVA on the maturation of
BMDCs, BMDCs were also treated with OVA, Man-MWCNTs or Man-
MWCNTs/OVA for 12 h. Then cells were washed with FACS buffer
and subsequently stained with anti-CD11c-PE  Cy7, anti-CD86-APC,
and anti-CD80-PE antibodies (eBioscience) for 30 min at 4 °C. These
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BMDCs were then sorted by flow cytometry after being washed
again with FACS buffer. All samples were done in triplicate.
Cytokine Detection
BMDCs were cultured with OVA, Man-MWCNTs or Man-MWCNTs/
OVA at 37 °C for 24 h. At the end of the experiment, the suspension
of BMDCs culture media was diluted for analysis. Interleukin-1β (IL-
1β), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α)
were analyzed with cytokine-specific ELISA kits respectively accord-
ing to the vendor‘s instructions. All samples were measured in
triplicate.
Statistical Analysis.
All the data are represented as mean� standard deviation (SD).
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